NYSE:RCUS Arcus Biosciences Q2 2025 Earnings Results & Report $22.84 +0.33 (+1.45%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more. Arcus Biosciences beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 6, 2025. The company reported EPS of -$1.1053 versus the -$1.14 consensus estimate, while revenue of $160.00 million topped the $32.86 million estimate by $127.14 million. Revenue increased 310.3% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 6, 2025TimeAfter Market ClosesConference Call4:05 PM ET Arcus Biosciences EPS ResultsActual EPS-$1.1053Consensus EPS -$1.14Beat/MissBeat by +$0.0347One Year Ago EPS-$1.02EPS Beat Rate6 of last 8 quartersArcus Biosciences Revenue ResultsActual Revenue$160.00 millionExpected Revenue$32.86 millionBeat/MissBeat by +$127.14 millionYoY Revenue Growth+310.30%Upcoming EarningsArcus Biosciences' Q3 2026 earnings is estimated for Tuesday, October 27, 2026, based on past reporting schedulesConference Call ResourcesSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Arcus Biosciences Q2 2025 Earnings FAQ Did Arcus Biosciences beat earnings estimates for Q2 2025? Arcus Biosciences (NYSE:RCUS) reported earnings of -$1.1053 per share for Q2 2025, beating the consensus estimate of -$1.14. The report was announced on Wednesday, August 6, 2025. What was Arcus Biosciences' revenue for Q2 2025? Arcus Biosciences reported revenue of $160.00 million for Q2 2025, against a consensus estimate of $32.86 million. When is Arcus Biosciences' next earnings date? Arcus Biosciences' next earnings date is estimated for Tuesday, October 27, 2026. MarketBeat tracks confirmed and estimated earnings dates for Arcus Biosciences on the company's earnings history page. Arcus Biosciences Earnings HeadlinesJPMorgan Initiates Coverage on Arcus Biosciences With Overweight Rating, $41 Price Target3 hours ago | marketscreener.comMArcus Biosciences, Inc. (NYSE:RCUS) Stock Has Average Price Target of $38.30October 11 at 2:15 AM | americanbankingnews.comTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.October 14 at 1:00 AM | Monument Traders Alliance (Ad)Arcus Biosciences Announces New Employment Inducement GrantsOctober 9, 2026 | businesswire.comArcus Biosciences Completes Early Cancer Trial for AB801, Setting Up Next Pipeline MovesOctober 9, 2026 | tipranks.comIs Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?October 7, 2026 | finance.yahoo.comSee More Arcus Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcus Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcus Biosciences and other key companies, straight to your email. Email Address About Arcus BiosciencesArcus Biosciences (NYSE:RCUS) is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation. Arcus’ oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist. These candidates are being evaluated in combination regimens and across multiple cancer types, including lung and gastrointestinal cancers. The company does not have a broad portfolio of marketed products and remains primarily focused on clinical-stage development. Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical development activities through collaborations and studies involving institutions and patients in the United States and other international markets. The company has maintained a strategic partnership with Gilead Sciences to advance and commercialize certain oncology programs. Arcus was co-founded and is led by Terry Rosen, Ph.D., who serves as chief executive officer.View Arcus Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
